Mark Cuban's Cost Plus Drugs moves into custom rare disease therapies
Start here
Mark Cuban's Cost Plus Drugs, known for low-cost generic medicines, is branching into personalized genetic medicines for rare diseases. Part of its new Dallas plant will be devoted to producing n-of-1 custom therapies, each made for a single patient. The first two batches are DNA-like molecules: one created by California chemists to repair a rare neuronal gene mutation in a single patient, and another developed with Dutch researchers as a treatment molecule for a progressive myopathy in adults. The move marks a strategic shift from the company's generics business into bespoke genetic medicines, an area where individual treatments have historically been impractical to manufacture at scale. Whether the Dallas facility can produce such therapies affordably and reliably, and which patients or conditions will be taken up next, has not yet been detailed.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- STATPickSTAT+: Mark Cuban wants to crack open the market for rare disease treatments
Mark Cuban's Cost Plus Drugs will devote part of its new Dallas plant's capacity to making n-of-1 custom rare disease therapies, shifting from cheap generics toward personalized genetic medicines. The first two batches are DNA-like molecules: one crafted by California chemists to patch a rare neuronal gene mutation in a single patient, and one developed with Dutch researchers to treat a progressive myopathy in adults. Cuban wrote in an email that it was an obvious chance to help those in an unfortunate situation.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 21 17:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.